PeerVoice Internal Medicine Audio

Visit https://www.peervoice.com/QWV860 to view the entire programme with slides. After completing “Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer”, participants will be able to: Describe antibody-drug conjugates (ADC)-based combination strategies that are in clinical development for HER2-positive metastatic breast cancer; Evaluate emerging updates on ADCs for the treatment of HER2-positive metastatic breast cancer; Assess therapeutic advances in hormone-receptor-positive metastatic breast cancer based on HER2 status in the context of current treatment guidelines; and Identify emerging ADC-based strategies being explored for high-risk HER2-positive early breast cancer.